CLINICAL IMMUNOLOGY
Neurodegenerative changes detected by neuroimaging in a patient with contiguous X-chromosome deletion syndrome encompassing BTK and TIMM8A genes
More details
Hide details
Submission date: 2017-07-06
Final revision date: 2017-09-01
Acceptance date: 2018-01-18
Publication date: 2018-06-30
Cent Eur J Immunol 2018;43(2):139-147
KEYWORDS
ABSTRACT
Introduction:
In this study we describe a patient with gross deletion containing the BTK and TIMM8A genes. Mutations in these genes are responsible for X-linked agammaglobulinemia and Mohr-Tranebjaerg syndrome, respectively. X linked agammaglobulinemia is a rare primary immunodeficiency characterized by low levels of B lymphocytes and recurrent microbial infections, whereas, Mohr-Tranebjaerg syndrome is a progressive neurodegenerative disorder with early onset of sensorineural deafness.
Material and methods:
For neuroimaging, the magnetic resonance imaging and magnetic resonance spectroscopy of the brain were performed. Microarray analysis was performed to establish the extent of deletion.
Results:
The first clinical symptoms observed in our patient at the age of 6 months were connected with primary humoral immunodeficiency, whereas clinical signs of MTS emerged in the third year
of live. Interestingly, the loss of speech ability was not accompanied by hearing failure. Neuroimaging of the brain suggested leukodystrophy. Molecular tests revealed contiguous X-chromosome deletion syndrome encompassing BTK (from exons 6 through 19) and TIMM8A genes. The loss of the patient’s DNA fragment was accurately localized from 100 601 727 to 100 617 576 bp on chromosome’s loci Xq22.1.
Conclusions:
We diagnosed XLA-MTS in the first Polish patient on the basis of particular molecular methods. We detected neurodegenerative changes in MRI and MR spectroscopy in this patient. Our results provide further insight into this rare syndrome.
REFERENCES (20)
1.
Winkelstein JA, Marino MC, Lederman HM, et al. (2006): X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore) 85: 193-202.
2.
Smith CIE, Berglöf A: X-Linked Agammaglobulinemia. In: GeneReviews® [Internet]. Pagon RA, Adam MP, Ardinger HH, et al. (eds.). University of Washington, Seattle 1998; 1993-2017.
3.
Tsukada S, Saffran DC, Rawlings DJ, et al. (1993): Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 72: 279-290.
4.
Vetrie D, Vořechovský I, Sideras P, et al. (2012): The gene involved in X-linked agammaglobulinaemia is a member of the Src family of protein-tyrosine kinases. J Immunol; 188: 2948-2955.
5.
Koehler CM, Leuenberger D, Merchant S, et al. (1999): Human deafness–dystonia syndrome is a mitochondrial disease. Proc Natl Acad Sci USA 96: 2141-2146.
6.
Jin H, Kendall E, Freeman TC, et al. (1999): The human family of deafness/dystonia peptide (DDP) related mitochondrial import proteins. Genomics 61: 259-267.
7.
Tranebjaerg L, Schwartz C, Eriksen H, et al. (1995): A new X linked recessive deafness syndrome with blindness, dystonia, fractures, and mental deficiency is linked to Xq22. J Med Genet 32: 257-263.
8.
Binder J, Hofmann S, Kreisel S, et al. Clinical and molecular findings in a patient with a novel mutation in the deafness-dystonia peptide (DDP1) gene. Brain, 2003,126:1814-1820.
9.
Ha AD, Parratt KL, Rendtorff ND, et al. (2012): The phenotypic spectrum of dystonia in Mohr-Tranebjaerg syndrome. Mov Disord 27: 1034-1040.
10.
Stenson PD, Ball EV, Mort M, et al. (2003): Human Gene Mutation Database (HGMD), 2003 update. Hum Mutat 21: 577-581.
11.
Jin H, May M, Tranebjaerg L, et al. (1996): A novel X-linked gene, DDP, shows mutations in families with deafness (DFN-1), dystonia, mental deficiency and blindness. Nat Genet 14: 177-180.
12.
Richter D, Conley ME, Rohrer J, et al. (2001): A contiguous deletion syndrome of X-linked agammaglobulinemia and sensorineural deafness. Pediatr Allergy Immunol 12: 107-111.
13.
Pizzuti A, Fabbrini G, Salehi L, et al. (2004): Focal dystonia caused by Mohr-Tranebjaerg syndrome with complete deletion of the DDP1 gene. Neurology 62: 1021-1022.
14.
Sedivá A, Smith CI, Asplund AC, et al. (2007): Contiguous X-chromosome deletion syndrome encompassing the BTK, TIMM8A, TAF7L, and DRP2 genes. J Clin Immunol 27: 640-646.
15.
Brookes JT, Kanis AB, Tan LY, et al. (2008): Cochlear implantation in deafness-dystonia-optic neuronopathy (DDON) syndrome. Int J Pediatr Otorhinolaryngol 72: 121-126.
16.
Jyonouchi H, Geng L, Törüner GA, et al. (2008): Monozygous twins with a microdeletion syndrome involving BTK, DDP1, and two other genes; evidence of intact dendritic cell development and TLR responses. Eur J Pediatr 167: 317-321.
17.
Arai T, Zhao M, Kanegane H, et al. (2011): Genetic analysis of contiguous X-chromosome deletion syndrome encompassing the BTK and TIMM8A genes. J Hum Genet 56: 577-582.
18.
Shaker M, Lorigiano TH, Vadlamudi A (2016): Xq22.1 contiguous gene deletion syndrome of X-linked agammaglobulinemia and Mohr-Tranebjćrg syndrome. Ann Allergy Asthma Immunol 116: 578-579.
19.
Jensen PK, Reske-Nielsen E, Hein-Sørensen O, Warburg M (1987): The syndrome of opticoacoustic nerve atrophy with dementia. Am J Med Genet 28: 517-518.
20.
Tranebjaerg L, Jensen PK, Van Ghelue M, et al. (2001): Neuronal cell death in the visual cortex is a prominent feature of the X-linked recessive mitochondrial deafness-dystonia syndrome caused by mutations in the TIMM8a gene. Ophthalmic Genet 22: 207-223.